**Effective Visual Communication (EVC) exercise: Case study**

**Efficacy of Capmatinib in Non Small Cell Lung Cancer (NSCLC) with MET mutations**

**Background:**

* Phase 2 study of Capmatinib (MET receptor inhibitor) in NSCLC patients with various MET mutations
* Primary endpoint: overall response (complete or partial response)
* Secondary endpoint: duration of response

**Key question:**

* Does Capmatinib show meaningful response in patients with various types of MET mutation?

**Reference** for additional background, purpose and key messages:

* Wolf et al. NEJM 2020, 383:944-957, <https://www.nejm.org/doi/full/10.1056/NEJMoa2002787>

**Task 1:**

* Complete the Purpose Worksheet (separate handout). It is already half filled.

**Task 2:**

* See the main visualization of the study results. Improve it or create your own to display the key message(s).

Chart

Description automatically generated